Sol-Gel Technologies Ltd. Stock

$0.56

3.93% yesterday

Nasdaq, Nov 25, 10:00 pm CET

ISIN

IL0011417206

Symbol

SLGL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Sol-Gel Technologies Ltd. Stock price

$0.56

-7.74 93.31% 5Y

Nasdaq, Closing price Mon, Nov 25 2024

+0.02 3.93%

ISIN

IL0011417206

Symbol

SLGL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$15.46m
Enterprise Value	$-11.28m
P/E (TTM) P/E ratio	negative
EV/Sales (TTM) EV/Sales	-0.96
P/S ratio (TTM) P/S ratio	1.32
P/B ratio (TTM) P/B ratio	0.45
Revenue growth (TTM) Revenue growth	603.12%
Revenue (TTM) Revenue	$11.71m
EBIT (operating result TTM) EBIT	$-11.36m
Cash position	$28.05m
EPS (TTM) EPS	$-0.34
P/E forward	negative
P/S forward	1.16
EV/Sales forward	negative
Short interest	0.31%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

Sol-Gel Technologies Ltd. Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Sol-Gel Technologies Ltd.:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Sol-Gel Technologies Ltd.:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Sol-Gel Technologies Ltd.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	12 12	601% 601% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	6.29 6.29	19% 19% 54%
- Research and Development Expense	17 17	29% 29% 143%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-11 -11	62% 62% -97%
Net Profit	-9.57 -9.57	65% 65% -82%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Sol-Gel Technologies Ltd. Stock News

Neutral

GlobeNewsWire

●

11 days ago

Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholders Phase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activated SGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pio...

Neutral

GlobeNewsWire

●

3 months ago

UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026 SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical nee...

Neutral

GlobeNewsWire

●

3 months ago

Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

More Sol-Gel Technologies Ltd. News

Company Profile

Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.

Head office	Israel
CEO	Alon Seri-Levy
Employees	36
Founded	1997
Website	www.sol-gel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now